Multicenter Evaluation of ABT-578 Elution From a Phosphorylcholine-coated Stent - ENDEAVOR-1

Oct 14, 2003
Font Size
A
A
A
Date Presented:
01/01/2003
Date Updated:
10/14/2003
Original Posted Date:
10/14/2003
References

Description:

This is a drug eluting stent registry using the Medtronics Driver cobalt alloy stent with phosphorylcholine coating eluting Abbott ABT-578.

Study Design

Study Design:

Patients Enrolled: 100

Patient Populations:

This is a multicenter-Australisian registry involving 100 patients with de novo lesions.

Lesion Diameter is 3.0 to 3.5mm

Lesion length is <15mm

Diabetes 16%

Primary Endpoints:

Endpoints were late loss at 4 months with angiographic and intravascular ultrasound follow-up and MACE.

Drug/Procedures Used:

The Driver stent is the latest generation thin strut stent from Medtronics.

ABT-578 is a sirolimus like compound.

Principal Findings:

There was one myocardial infarction at 4 months and 1 TLR.

Late loss was 0.33mm in stent and 0.20mm in segment.

Angiographic percent diameter stenosis was 14.4% in stent and 21.7% insegment.

Neointimal volume was 61mm3 representing 4.5% of the stent volume.

Interpretation:

The Medtronic drug eluting stent seems to be effective in the short term (4 months) except for higher than expected late loss in a low risk group of patients (low diabetes percent and larger vessel size).

References:

Presented at Late-breaking Clinical Trials, TCT 2003, Washington, DC.

Keywords: Myocardial Infarction, Coronary Restenosis, Coronary Stenosis, Cobalt, Drug-Eluting Stents, Constriction, Pathologic, Sirolimus, Phosphorylcholine, Diabetes Mellitus


< Back to Listings